(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), Monday announced the launch of an authorized generic for Victoza injection with a quantity of 1.8 mg for type 2 diabetes patients in the U.S.
The injectable prescription medicine helps in lowering blood sugar levels in adults and children who are 10 years of age and older with type 2 diabetes mellitus, and reduces risk of cardiovascular disease, the company stated.
The biotechnology company added that Victoza had annual sales of $1.656 billion as of April 2024.
Currently, Teva's stock is falling 1.98 percent, to $16.63 on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
